GSK_Annual_Report_2021

Annual Report 2020-21 45 11 Compliance with secretarial standards The Board of Directors affirms that the Company has complied with the applicable Secretarial Standards issued by the Institute of Companies Secretaries of India (SS1 and SS2) respectively, relating to Meetings of the Board and its Committees which have mandatory application. 12. General The information on conservation of energy, technology absorption and foreign exchange earnings and outgo, as stipulated in section 134(3) M of the Companies Act, 2013 and the rules framed thereunder, is attached herewith as Annexure ’E’ , which forms a part of this Report. The disclosures pertaining to the remuneration and other details, as required under section 197(12) of the Companies Act, 2013, and the rules made thereunder, are enclosed as Annexure ’F’ , which forms a part of this Report. Pursuant to section 129(3) of the Companies Act, 2013, a statement in form “AOC-1” , containing salient features of the Financial Statements of the Subsidiary Company, is attached. Although the audited statements of accounts relating to the Company’s Subsidiary are no longer required to be attached to the Company’s Annual Report, the same is enclosed as and in way of better disclosure practice. The information relating to top ten employees in terms of remuneration and employees, who were in receipt of remuneration of not less than ` 1.02 cores during the year or ` 8.5 lakhs per month during any part of the year, forms part of this report and will be provided to any shareholder on a written request to the Company Secretary. In terms of Section 136 of the Act, the said report will be available for inspection of the shareholders through electronic mode. The shareholders may write an email to askus@gsk.com by mentioning “Request for Inspection” in the subject of the email. 13. Acknowledgments The Directors express their appreciation for the contribution made by the employees for remarkable agility and resilience throughout the year in unprecedented circumstances including significant improvement in the operations of the Company and also for the support received from all other stakeholders, including Shareholders, doctors, medical professionals, customers, suppliers, business partners and the government. The Board and the Management of your Company are appreciative of the support being received from GSK plc. On behalf of the Board of Directors Ms. R. S. Karnad Mumbai, 18 May 2021 Chairperson